Published in Antimicrob Agents Chemother on April 05, 2010
Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev (2012) 5.65
"Stormy waters ahead": global emergence of carbapenemases. Front Microbiol (2013) 2.74
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc (2011) 1.89
Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis (2011) 1.64
Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother (2013) 1.27
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2012) 1.25
Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis (2012) 1.20
Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother (2014) 1.14
Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria. Microbiol Insights (2016) 1.13
β -Lactamase-Producing Multidrug-Resistant Bacterial Pathogens from Tracheal Aspirates of Intensive Care Unit Patients at National Institute of Neurological and Allied Sciences, Nepal. ISRN Microbiol (2013) 1.01
In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2013) 0.93
Carbapenemase-producing Klebsiella pneumoniae. F1000Prime Rep (2014) 0.91
Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. Ups J Med Sci (2014) 0.90
Polymyxin Combination Therapy and the Use of Serum Bactericidal Titers in the Management of KPC-Producing Klebsiella pneumoniae Infections: A Report of 3 Cases. Case Rep Med (2011) 0.88
Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy (2015) 0.86
In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother (2015) 0.83
Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model. Antimicrob Agents Chemother (2012) 0.80
Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model. Oncotarget (2015) 0.80
Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae. Virulence (2016) 0.78
Effects of various antibiotics alone or in combination with doripenem against Klebsiella pneumoniae strains isolated in an intensive care unit. Biomed Res Int (2014) 0.78
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase. Antimicrob Agents Chemother (2016) 0.77
Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2016) 0.77
Simultaneous use of other antimicrobials may have influenced clinical outcomes. Clin Infect Dis (2011) 0.75
Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infect Dis Ther (2015) 0.75
New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2017) 0.75
Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy. J Microbiol (2017) 0.75
Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev (2007) 15.82
Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis (2004) 9.21
Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother (2005) 4.17
A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis (2007) 3.39
Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn Microbiol Infect Dis (2006) 3.21
Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents (1999) 2.64
Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis (2009) 2.19
Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin Infect Dis (2008) 1.97
Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect (2008) 1.82
In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2004) 1.72
Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob Agents Chemother (2004) 1.65
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis (2005) 1.61
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob Agents Chemother (2009) 1.37
Polymyxin B and rifampin: new regimen for multiresistant Serratia marcescens infections. Antimicrob Agents Chemother (1977) 1.30
Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis (2006) 1.26
Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis (2006) 0.90
Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis (2004) 9.21
Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin Infect Dis (2008) 1.97
Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis (2003) 1.91
Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis (2002) 1.75
In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2004) 1.72
Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagn Microbiol Infect Dis (2010) 1.35
Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology. Clin Infect Dis (2004) 1.30
Identification of carbapenem-resistant klebsiella pneumoniae harboring KPC enzymes in New Jersey. Microb Drug Resist (2007) 1.27
Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV. Antimicrob Agents Chemother (2004) 1.20
Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob Agents Chemother (2005) 1.09
Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother (2004) 1.04
Identification of CTX-M β-lactamases among Escherichia coli from the community in New York City. Diagn Microbiol Infect Dis (2012) 1.01
Health care-associated infection (HAI): a critical appraisal of the emerging threat-proceedings of the HAI Summit. Clin Infect Dis (2008) 0.97
Polymyxin-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother (2010) 0.94
Increased mortality associated with a clonal outbreak of ceftazidime-resistant Klebsiella pneumoniae: a case-control study. Infect Control Hosp Epidemiol (2005) 0.90
Polymyxin Combination Therapy and the Use of Serum Bactericidal Titers in the Management of KPC-Producing Klebsiella pneumoniae Infections: A Report of 3 Cases. Case Rep Med (2011) 0.88
Community-associated Escherichia coli harboring CTX-M β-lactamases from urine cultures from pediatric patients. Antimicrob Agents Chemother (2012) 0.86
Impact of contact and droplet precautions on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus infection. Infect Control Hosp Epidemiol (2007) 0.85
An outbreak of domestically acquired typhoid fever in Queens, NY. Arch Intern Med (2004) 0.81
Unrelated strain methicillin-resistant Staphylococcus aureus colonization of health care workers in a neonatal intensive care unit: findings of an outbreak investigation. Am J Infect Control (2013) 0.81
Mycobacterial infection as a precursor to sarcoid-like, corticosteroid-responsive, diffuse granulomatous disease. Int J Infect Dis (2006) 0.79
Identification of extended-spectrum-β-lactamase-positive Klebsiella pneumoniae urinary tract isolates harboring KPC and CTX-M β-lactamases in nonhospitalized patients. Antimicrob Agents Chemother (2013) 0.77
Phenotypic and genotypic screening and clonal analysis of carbapenem-resistant Klebsiella pneumoniae at a single hospital. Microb Drug Resist (2011) 0.77
Use of daptomycin for the treatment of methicillin-resistant coagulase-negative staphylococcal ventriculitis. Case Rep Med (2012) 0.75